Jones Trading upgraded Editas Medicine (NasdaqGS:EDIT) from Hold to Buy on March 10, 2026, with an analyst price forecast implying 100.70% upside. The upgrade represents a material positive signal for investor sentiment and could prompt a re-rating of the stock, likely moving the share price by a few percent in the short term. The report provides no additional company-specific fundamentals or catalysts beyond the price-target-driven upgrade.
Jones Trading upgraded Editas Medicine (NasdaqGS:EDIT) from Hold to Buy on March 10, 2026, with an analyst price forecast implying 100.70% upside. The upgrade represents a material positive signal for investor sentiment and could prompt a re-rating of the stock, likely moving the share price by a few percent in the short term. The report provides no additional company-specific fundamentals or catalysts beyond the price-target-driven upgrade.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately positive
Sentiment Score
0.60
Ticker Sentiment
